Dec 22, 2020 6:25pm EST Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering
Dec 03, 2020 8:30am EST Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration
Jul 27, 2020 11:28am EDT Inhibikase Files Registration Statement for Proposed Initial Public Offering
Apr 09, 2019 8:00am EDT Inhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors
Mar 19, 2019 8:00am EDT Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson’s Disease
Mar 05, 2019 8:00am EST Inhibikase Therapeutics Appoints Leading Experts in Parkinson’s Disease to its Scientific Advisory Board
Feb 26, 2019 8:00am EST Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease
